Corporate Announcements
- CuraTeQ Biologics announces the successful Phase 1 clinical study outcome of their BP11 product (a biosimilar to Xolair)
- Eugia Pharma receives USFDA Approval for Posaconazole Injection, 300 mg/16.7 mL (18 mg/mL), Single-Dose Vial
- BUDESONIDE INHALATION APPROVAL
- DARUNAVIR TAB APPROVAL
- RYZENEUTA USFDA APPROVAL
- TESTOSTERONE CYPRIONATE INJ APPROVAL
- ANTI HIV TRIPLE COMBINATION LAUNCH
- VANCOMYCIN INJ APPROVAL
- SAXAGLIPTIN TAB APPROVAL
- PLERIXAFOR INJ USFDA APPROVAL
- SEVELAMER HCL TAB APPROVAL
- TRASTUZUMAB BIOSIMILAR POSITIVE P3 RESULT
- MPP GX NILOTINIB LICENSING
- CARBOPROST TROMETHAMINE APPROVAL